Asuragen to Host Panel at Upcoming World Clinical Biomarkers & Companion Diagnostic Summit
AUSTIN, Texas--(BUSINESS WIRE)-- Asuragen, Inc., a molecular diagnostics company delivering easy to use products for complex testing in genetics and oncology, announced that it will be hosting a pre-conference workshop October 2nd during the 2018 World Clinical Biomarkers & Companion Diagnostic Summit in Boston. The session will highlight the escalating economic and human burden caused by neurodegenerative diseases and will review strategies to help overcome the scientific challenges and align key stakeholders to improve the level of care afforded these patients.
“The benefit of precision medicine has been demonstrated across multiple cancers, but disease areas like neurology have yet to benefit from such advances,” said Matthew McManus, M.D., Ph.D., president and CEO of Asuragen. “Imagine the impact precision medicine could have on the standard of care and our healthcare system for neurodegenerative diseases. It’s an ambitious and worthy goal for our industry. ”
The panel discussion, titled “New Horizons in Complementary and Companion Diagnostics – To Neurology and Beyond,” will take place from 9 a.m. – 12:30 p.m. on Tuesday, October 2. The panel assembles key thought leaders from across the industry to provide their unique perspectives. The participants include Ornit Chiba-Falek, Ph.D., associate professor, Department of Neurology, Duke University Medical Center; Gary Latham, Ph.D., senior vice president of research and development, Asuragen; Gary Gustavsen, partner at Health Advances; and Bernard Andruss, Ph.D., senior vice president of operations and regulatory affairs, Asuragen. The discussion will address several issues facing both the pharmaceutical and diagnostic industries, including the challenges of identifying predictive biomarkers in these diseases, the role of new technologies in developing and implementing fit-for-purpose tests to screen for appropriate patients, and how to ease the pressure on an overburdened healthcare system before these breakthroughs reach the clinic.
Asuragen is a molecular diagnostic product company changing the way patients are treated in genetics and oncology. Asuragen’s diagnostic systems, composed of proprietary chemistry and software, deliver powerful answers using broadly installed instrument platforms. They are simple to adopt and expand the ability to serve patients. Asuragen is a product foundry rapidly and efficiently addressing current and emerging clinical needs, including cancer diagnosis and monitoring, reproductive health and aging, serving laboratories across a patient’s lifespan with its best in class diagnostic tests. For more information, visit www.asuragen.com.
Lynne Hohlfeld, 512-681-5200
SVP, Corporate Development and CFO
Source: Asuragen, Inc.